The stock markets have ended the week on bullish momentum. The Nasdaq Stock Market rose by 1.02 % and the New York Stock Exchange also rose by 1.55% on Friday.
Even though the markets are facing some uncertainty, investors are still looking for a good deal. Here is a list of 2 stocks that have a quarterly revenue growth (YoY) above 30%. May these stocks be a good medium-term investment option?
1 - Arbor Realty Trust
Arbor Realty Trust, Inc. invests in a diversified portfolio of structured finance assets in the multifamily, single-family rental, and commercial real estate markets.
Arbor Realty Trust sales growth this year is expected to be 26.9 % and -0.1 % for next year.
Year-on-year quarterly revenue growth grew by 30.5 %.
Arbor Realty Trust's sales growth for the next quarter is 12.2 %. The company's growth estimates for the ongoing quarter and the next are -11.8% and 151.9%, respectively. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.16%.
Arbor Realty Trust's stock is worthed at $ 12.76, way above its 52 Week High of $ 15.77 way below its 52 Week Low of $ 3.54.
Arbor Realty Trust's worth is higher than its 50 day moving average of $11.7.
Arbor Realty Trust's worth is way higher than its 200 day moving average of $9.79.
2 - O2Micro International Limited
O2Micro International Limited, together with its subsidiaries, designs, develops, and markets integrated circuits and solutions for power management components and systems in China, the United States, Taiwan, Japan, Malaysia, Korea, Singapore, and internationally.
O2Micro International Limited sales growth this year is anticipated to be 25.9 % and 13 % for next year.
Year-on-year quarterly revenue growth grew by 38.7%.
O2Micro International Limited's next quarter sales growth is 50.2% The company's growth estimates for the present quarter and the next are 20% and 150%, respectively. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.71%.
O2Micro International Limited's stock is valued at $7.25, below its 52 Week High of $8.35 and way above its 52 Week Low of $0.98.
O2Micro International Limited's worth is way above than its 50 day moving average of $ 4.85.
O2Micro International Limited's worth is way above than its 200 day moving average of $ 2.78.
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
